吸附|年终巨献:与人类“同居”两年,改变世界的新冠病毒究竟为何物丨奇点深度( 五 )


[22].https://www.who.int/en/activities/tracking-SARS-CoV-2-variants
[23].Cao Y R, Wang J, Jian F, et al. B. 1.1. 529 escapes the majority of SARS-CoV-2 neutralizing antibodies of diverse epitopes[J]. BioRxiv, 2021.
[24].Maslo C, Friedland R, Toubkin M, et al. Characteristics and outcomes of hospitalized patients in South Africa during the COVID-19 Omicron wave compared with previous waves[J]. JAMA, 2021.
[25].Wolter N, Jassat W, Walaza S, et al. Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study[J]. The Lancet, 2022.
[26].Johnson A G. COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence—25 US Jurisdictions, April 4–December 25, 2021[J]. MMWR. Morbidity and Mortality Weekly Report, 2022, 71.
[27].Shuai H, Chan J F W, Hu B, et al. Attenuated replication and pathogenicity of SARS-CoV-2 B. 1.1. 529 Omicron[J]. Nature, 2022: 1-1.
[28].Burki T K. Omicron variant and booster COVID-19 vaccines[J]. The Lancet Respiratory Medicine, 2021.
[29].Nishiura H, Ito K, Anzai A, et al. Relative reproduction number of SARS-CoV-2 Omicron (B. 1.1. 529) compared with Delta variant in South Africa[J]. Journal of clinical medicine, 2022, 11(1): 30.
[30].Dejnirattisai W, Huo J, Zhou D, et al. Omicron-B. 1.1. 529 leads to widespread escape from neutralizing antibody responses[J]. 2021.
[32].Liu L, Iketani S, Guo Y, et al. Striking Antibody Evasion Manifested by the Omicron Variant of SARS-CoV-2[J]. nature, 2021.
[33].Vangeel L, De Jonghe S, Maes P, et al. Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern[J]. bioRxiv, 2021.
[34].Dabrowska A, Szczepanski A, Botwina P, et al. Efficacy of antiviral drugs against the omicron variant of SARS-CoV-2[J]. bioRxiv, 2021.
本文作者丨BioTalker